US Stock Market Move | BeOne Medicines Ltd. (ONC.US) rose more than 6% in pre-market trading, with net profit for the first three quarters up 431.8% year on year.

On Thursday, BeOne Medicines Ltd. (ONC.US) rose more than 6% in pre-market trading to $402.98. Financial results showed that BeOne Medicines Ltd. achieved total operating revenue of RMB34.993 billion in the first three quarters, up 26.8% year on year; net profit attributable to shareholders was RMB6.055 billion, up 431.8% year on year. On a quarterly basis, the company achieved total operating revenue of RMB12.774 billion in the third quarter, up 26.8% year on year; net profit attributable to shareholders was RMB2.785 billion, up 304.3% year on year. In the third quarter of 2026, the company's product revenue was RMB12.560 billion, compared with product revenue of RMB9.954 billion in the same period last year. The growth in product revenue was mainly driven by sales growth of its self-developed products BRUKINSA (zanubrutinib capsules) and TEVIMBRA (tislelizumab injection), as well as Amgen-licensed products. BeOne Medicines Ltd. further raised its full-year guidance: the company expects 2026 operating revenue to be between RMB46.3 billion and RMB47.0 billion, up from its previous forecast of RMB44.9 billion to RMB46.2 billion.